Retinitis Pigmentosa: Gene Therapy Restores Vision
- SALT LAKE CITY — Patients with retinitis pigmentosa experienced lasting improvements in visual acuity after treatment with MCO-010, according to SriniVas R.
- The gene therapy, developed by Nanoscope Therapeutics, also demonstrated a favorable safety profile, Sadda said.
- Sadda noted the growing interest in optogenetic therapies for inherited retinal dystrophies.MCO-010 is currently the most advanced therapy in this area.
Patients with retinitis pigmentosa are seeing lasting improvements: gene therapy is showing promise. According to a study presented at the ARVO meeting, MCO-010 therapy is demonstrating enduring visual acuity gains, marking a significant step forward for those battling this inherited retinal disease. The therapy, developed by Nanoscope Therapeutics, also exhibits a favorable safety profile, offering renewed hope. News Directory 3 keeps you informed on these groundbreaking advancements. With the growing focus on optogenetic therapies, MCO-010 currently leads the way. Research continues on broader applications for retinitis pigmentosa and other inherited retinal diseases.Discover what’s next for future vision restoration.
Gene Therapy Shows Promise for Retinitis Pigmentosa Treatment
Updated June 13, 2025
SALT LAKE CITY — Patients with retinitis pigmentosa experienced lasting improvements in visual acuity after treatment with MCO-010, according to SriniVas R. Sadda, MD, FARVO. He discussed the 126-week outcomes of the study at the ARVO meeting.
The gene therapy, developed by Nanoscope Therapeutics, also demonstrated a favorable safety profile, Sadda said.
Sadda noted the growing interest in optogenetic therapies for inherited retinal dystrophies.MCO-010 is currently the most advanced therapy in this area.
Sources/Disclosures
Sadda SR, et al. 126-week visual acuity outcomes following mutation-agnostic optogenetic therapy, MCO-010, for retinitis pigmentosa. Presented at: Association for research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.
Sadda reports consulting for Nanoscope Therapeutics.
What’s next
Further research will focus on long-term efficacy and broader applications of gene therapy for retinitis pigmentosa and other inherited retinal diseases.